Michael Foley

Co-Founder at FORMA Therapeutics, Inc.

Michael Foley

Michael Foley

Co-Founder at FORMA Therapeutics, Inc.

Overview
Career Highlights

Deerfield Management LP
Deerfield Discovery & Development LLC
FORMA Therapeutics, Inc.

RelSci Relationships

769

Number of Boards

6

Birthday

1962

Age

59

Relationships
RelSci Relationships are individuals Michael Foley likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Chief Financial Officer & Senior Vice President at Takeda Oncology Co.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Forma Therapeutics Holdings LLC

Relationship likelihood: Strong

Chief Executive Officer & Director at Gammadelta Therapeutics Ltd.

Relationship likelihood: Strong

Founder at FORMA Therapeutics, Inc.

Relationship likelihood: Strong

Former Executive Chairman at ZappRx, Inc.

Relationship likelihood: Strong

President & Director at The Broad Institute, Inc.

Relationship likelihood: Strong

General Partner at Lilly Ventures Management Co. LLC

Relationship likelihood: Strong

Managing Director at Novartis Venture Fund

Relationship likelihood: Strong

Founder at Eli & Edythe Broad Foundation

Relationship likelihood: Strong

President at Society For Neuroscience

Relationship likelihood: Strong

Paths to Michael Foley
Potential Connections via
Relationship Science
You
Michael Foley
Co-Founder at FORMA Therapeutics, Inc.
Education
M.S. in Chemistry

Utah State University (USU) is a public research university in Logan, Utah. Founded in 1888 as Utah's agricultural college, USU focused on agriculture, domestic arts, and mechanic arts. The university now offers programs in liberal arts, engineering, business, economics, natural resource sciences, as well as nationally ranked elementary & secondary education programs. The university has eight colleges and offers a total of 176 bachelor's degrees, 97 master's degrees, and 38 doctoral degrees. It is a land-grant and space-grant institution accredited by the Northwest Commission on Colleges and Universities. USU's main campus is located in Logan with regional campuses in Brigham City, Tooele, and the Uintah Basin. In 2010, the College of Eastern Utah, located in Price, Utah joined the USU system becoming Utah State University College of Eastern Utah (USU Eastern). Throughout Utah, USU operates more than 20 distance education centers. Regional campuses, USU Eastern, and distance education centers provide degrees to more than 40% of the students enrolled. In total, USU has more than 180,000 alumni in all 50 states and more than 100 countries. With more than 16,000 students living on or near campus, USU is the largest public residential campus in Utah. USU's athletic teams compete in Division I of the NCAA and are collectively known as the Utah State Aggies. They are members of the Mountain West Conference.

B.S. in Chemistry

St. Norbert College is a private Catholic liberal arts college in De Pere, Wisconsin. Founded in October 1898 by Abbot Bernard Pennings, a Norbertine priest and educator, the school was named after Saint Norbert of Xanten. In 1952, the college became coeducational. The school currently enrolls about 2,175 students.

PhD

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

Career History
Co-Founder
2000 - Prior

CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA

Professional
Prior
Co-Founder
1995 - Prior

Infinity is an innovative drug discovery and development company dedicated to discovering, developing and delivering to patients best-in-class medicines for diseases with significant unmet need. We believe that our small molecule discovery and development capabilities, strategic alliances, team of highly experienced management and scientists, and corporate culture form the basis of our potential long-term competitive advantage in seeking to deliver best-in-class medicines to patients

Boards & Committees
Member, Board of Directors
Current

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA.

Independent Non-Executive Director
2007 - 2020

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

Director
Tenure Unconfirmed

Quentis Therapeutics, Inc. operates as a biotechnology company. It develops therapeutics in the onco-immunology field. The company was founded by Juan R. cubillos-Ruiz and is headquartered in New York, NY.

Board Member
Current

St. Norbert College is a private Catholic liberal arts college in De Pere, Wisconsin. Founded in October 1898 by Abbot Bernard Pennings, a Norbertine priest and educator, the school was named after Saint Norbert of Xanten. In 1952, the college became coeducational. The school currently enrolls about 2,175 students.

Vice President, Executive Committee
Current
Member, Management Committee
Prior

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$100 - $499
2012

St. Norbert College is a private Catholic liberal arts college in De Pere, Wisconsin. Founded in October 1898 by Abbot Bernard Pennings, a Norbertine priest and educator, the school was named after Saint Norbert of Xanten. In 1952, the college became coeducational. The school currently enrolls about 2,175 students.

$100 - $499
2011

St. Norbert College is a private Catholic liberal arts college in De Pere, Wisconsin. Founded in October 1898 by Abbot Bernard Pennings, a Norbertine priest and educator, the school was named after Saint Norbert of Xanten. In 1952, the college became coeducational. The school currently enrolls about 2,175 students.

Political Donations
$25
2009
$25
2009
$100
2008

NO on 8-Equality for All campaign is a large and diverse coalition of civil rights, faith, choice, labor and community of color organizations working to stop and defeat any ballot measure that would deny same-sex couples the right to marry in California.

Investments
Details Hidden

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

Details Hidden

CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael Foley. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael Foley's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael Foley.